Lipitor Unlikely To Meet 2006 Guidance, Pfizer Acknowledges
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer Vice Chairman David Shedlarz says, however, that the $13 bil. projection will not be missed “by a mile.”
You may also be interested in...
Pfizer Restructuring Expands Shedlarz' Responsibilities As Katen Departs
New CEO Jeffrey Kindler also establishes a seven member "Executive Leadership Team."
Pfizer Could Expect Major Lipitor Sales Decline By 2007, Report Says
Most doctors expect to start patients on a generic statin, according to a survey by Decision Resources.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter